Top Banner
P ulmonary embolism: Risks,Diagnosis, Prevention & Treatment
33
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Pumonary embolism vkas

Pulmonary embolism:Risks,Diagnosis,

Prevention & Treatment

Page 2: Pumonary embolism vkas

Pulmonary Embolism

• Blockade of pulmonary artery/branches by a substance travelling from elsewhere through the bloodstream

Page 3: Pumonary embolism vkas

• Thrombotic• Non-thrombotic

– Fat– Amniotic fluid– Air– Tumor tissue– Foreign body

Page 4: Pumonary embolism vkas

Variable presentation:

– Massive (5%)

– Sub massive (25%)

– Non-massive (70%)

Page 5: Pumonary embolism vkas

Epidemiology

• 1 in 1000 cases per year ! (US)

• PE present 60-80% with DVT !>half asymptomatic thou

• 79% of patients with PE have DVT

Page 6: Pumonary embolism vkas

Pathophysiology

• DVT and PE occur as a continuum

• Virchow’s Triad: (1856)

– Blood flow changes (stasis,turbulence)

– Vessel injury

– Hpercoagulability

Page 7: Pumonary embolism vkas

(Serotonin,thromboxane)

Page 8: Pumonary embolism vkas

Predisposing factors

– Age (>60 yrs)

– history of previous VTE

– active cancer

– Prolonged bed rest, such as heart or acute respiratory failure, obesity, neurological disease

– congenital or acquired thrombophilia

– hormone replacement therapy

– oral contraceptive therapy

– Pregnancy

Page 9: Pumonary embolism vkas

– Surgery ( knee surgery, major general surgery)

– Trauma ( hip fracture, spinal cord injury)

– Central venous line

– Chemotherapy

Page 10: Pumonary embolism vkas

Inherited Risk Factors

• Protein C resistance (Factor V Leiden)

• -Antithrombin III deficiency

• -Protein C deficiency

• -Protein S deficiency

• -Hyperhomocystinemia (? Acquired due to vit.B1/B6 deficiency)

• Antiphospholipid antibody

The investigation of states in theacute phase of thromboembolic disease must necessarily include checks for: a) Factor V Leiden, becauseit is the most common anomaly responsibleusing polymerase chain reaction; b) Hyperhomocysteinaemiamay usually be treated completely and quickly by the administration of vitaminsB1and B6; c) Lupus anticoagulant, because if it is present it requires intensive and immediate therapy. Inthe acute phase it is not necessary to check proteinC, protein S, or because theyare rarely deficient, and secondly because their levels

Page 11: Pumonary embolism vkas

Diagnosis

Page 12: Pumonary embolism vkas

Symptoms

– Dyspnoea– Chest pain (pleuritic, substernal) – Cough – Hemoptysis – Syncope

Page 13: Pumonary embolism vkas

Physical Signs

• Tachypnea (>16/min) 96%• Rales 58%• Accentuated S2: 53%• Tachycardia : 44 %• Fever (>37.80C): 43%• S3 or S4 gallop: 34 %• Signs/symptoms suggesting thrombophlebitis 32%• Leg edema : 24 %• Murmur : 23 %• Cyanosis: 19 %

Page 14: Pumonary embolism vkas

PE Wells scoreClinical feature Points

Clinical signs and symptoms of DVT (minimum of leg swelling and pain

with palpation of the deep veins)3

An alternative diagnosis less likely than PE 3

Heart rate > 100 beats per minute 1.5

Immobilisation more than 3 days/surgery in previous 4 weeks 1.5

Previous DVT/PE 1.5

Haemoptysis 1

Malignancy (on treatment/treated in the past 6 months/palliative) 1

Clinical probability simplified scores

PE likely More than 4

PE unlikely 4 or less

a Adapted with permission from Wells PS et al. (2000) Derivation of a simple clinical model to categorize patients’

probability of pulmonary embolism: increasing the model’s utility with the SimpliRED D-dimer. Thrombosis and

Haemostasis 83: 416–20

Page 15: Pumonary embolism vkas

Revised Geneva Scoring system

• RISK FACTORS• Age >65 1• Previous DVT/PE 3• Surgery/ # of lower limg < 1 mnth 2• Malignancy 2• SYMPTOMS• Unilateral lower limb pain 3• Hemoptysis 2• SIGNS• HR (75-94) 3• HR (>95) 5• Pain/unilateral leg edema 4

0-3 low,4-10 intermediate,>11 high. 25 max

Page 16: Pumonary embolism vkas

Investigations

Page 17: Pumonary embolism vkas

• CXResp. helpful in ruling out other causes (pneumonia/thorax)

• ECG– S1Q3T3 (insensitive without clinical symptom)– inversion of T waves in leads V1–V4– RAD, right bundle-branch block– AF

Page 18: Pumonary embolism vkas

• ABGs

• Nonspecific

• hypoxemia,hypocapnia & resp. Alkalosis ↑A-a gradient

• However,Low PO2 has strong PPV for pts without respi. diseases

Page 19: Pumonary embolism vkas

• D-dimer – Fibrin degradation product– elevated in the presence of thrombus.- has a negative predictive value. - a sensitivity for venous thromboembolism of 95-97% and a specificity of 45%. - D-dimer < 500 ng/mL using ELISA provides strong evidence against venous thromboembolism.

Page 20: Pumonary embolism vkas

• Ischemia modified Albumin (IMA)

• Albumin produced during ischemia

• 93 % sensitive, 75% Specific for PE combined with scoring systems

• ↑ in MI, ACS

Page 21: Pumonary embolism vkas

• CT - large, central PE

• PUL. ANGIOGRAPHY– emboli as small as 1 to 2 mm

• Lung V/Q Scanning • The perfusion scan defect indicates absent or decreased

blood flow due to PE. -Ventilation scans improve the specificity of the perfusion scan. - A high probability scan is defined as two or more segmental

perfusion defects in presence of normal ventilation scan.

Page 22: Pumonary embolism vkas

Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing

in primary care: prospective cohort studyBMJ 2012; 345 doi

• Abstract Geert-Jan Geersing,• Design Prospective cohort study.• Setting Primary care across three different regions of the Netherlands (Amsterdam, Maastricht, and

Utrecht).• Participants 598 adults with suspected pulmonary embolism in primary care.• Interventions Doctors scored patients according to the seven variables of the Wells rule and carried

out a qualitative point of care D-dimer test. All patients were referred to secondary care and diagnosed according to local protocols. Pulmonary embolism was confirmed or refuted on the basis of a composite reference standard, including spiral computed tomography and three months’ follow-up.

• Main outcome measures Diagnostic accuracy (sensitivity and specificity), proportion of patients at low risk (efficiency), number of missed patients with pulmonary embolism in low risk category (false negative rate), and the presence of symptomatic venous thromboembolism, based on the composite reference standard, including events during the follow-up period of three months.

• Results Pulmonary embolism was present in 73 patients (prevalence 12.2%). On the basis of a threshold Wells score of ≤4 and a negative qualitative D-dimer test result, 272 of 598 patients were classified as low risk (efficiency 45.5%). Four cases of pulmonary embolism were observed in these 272 patients (false negative rate 1.5%, 95% confidence interval 0.4% to 3.7%). The sensitivity and specificity of this combined diagnostic approach was 94.5% (86.6% to 98.5%) and 51.0% (46.7% to 55.4%), respectively.

• Conclusion A Wells score of ≤4 combined with a negative qualitative D-dimer test result can safely and efficiently exclude pulmonary embolism in primary care.

Page 23: Pumonary embolism vkas

Treatment

Page 24: Pumonary embolism vkas
Page 25: Pumonary embolism vkas

• Hemodynamic and respiratory support– Rest & Oxygen– Inotropic support +/-– Mechanical ventilation

Page 26: Pumonary embolism vkas

Anticoagulation

Unfractionated Heparin– catalyzes the inactivation of thrombin and factor Xa by

antithrombin– an initial bolus of 80 IU/kg IV, followed by a continuous

infusion of 18 IU/kg/hr IV. – Rate of the heparin infusion adjusted so that the aPTT is

1.5-2.5 times the control value.

Page 27: Pumonary embolism vkas

• LMWH

– inactivates factor Xa , minimally prolongs aPTT

– does not require monitoring of its anticoagulant effect (predictable dose-response relationship)

– lower risk of bleeding complications and thrombocytopenia.

– less protein C and S inhibition, less complement activation, and a lower risk of osteoporosis

– Enoxaparin- 1 mg/kg SC BD or 1.5 mg/kg OD

Page 28: Pumonary embolism vkas

• Warfarin

started after therapeutic heparinization.

o Oral anticoagulant inhibits reduction of vit K to its active form depletion of vit K dependent clotting factors (2,7,9,10)

o difficult dosing, frequent monitoring, notorious interaction with other drugs/food

Page 29: Pumonary embolism vkas

• Direct factor Xa inhibitors• predictable anticoagulation• no need for dose adjustments and routine coagulation monitoring

• Rivaroxaban, Apixaban

Page 30: Pumonary embolism vkas

• Thrombolysisstreptokinase, Urokinase, rTPA

o Massive PE

o Hemod. Unstability, Circulatory shock

Page 31: Pumonary embolism vkas

• Venous filter (IVC filter)– contraindications for anticoagulant (active haemorrhage, endangered

haemorrhage following severe brain injury or craniotomy)

– repeated episodes of PE occur despite anticoagulant therapy

• Pulmonary embolectomyfailed/contraindicated thrombolysis

Page 32: Pumonary embolism vkas

Anesthetic concerns

• Maintain organ perfusion and avoid myocardial depression

• Avoid

– arterial hypoxemia,

– systemic hypotension

– pulmonary hypertension

– Histamine releasing NMBD

Page 33: Pumonary embolism vkas

Amniotic fluid embolism

• amniotic fluid, fetal cells, hair, or other debris enters the mother's blood stream via the placental bed of the uterus and trigger an allergic reaction

• three prerequisites:

• Ruptured membranes (a term used to define the rupture of the amniotic sac

• Ruptured uterine or cervical veins

• A pressure gradient from uterus to vein